TY - JOUR T1 - Improvements in clinical signs of Parkinson’s disease using photobiomodulation: A prospective proof-of-concept study JF - medRxiv DO - 10.1101/2021.05.26.21257833 SP - 2021.05.26.21257833 AU - Ann Liebert AU - Brian Bicknell AU - E-Liisa Laakso AU - Gillian Heller AU - Parastoo Jalilitabaei AU - Sharon Tilley AU - John Mitrofanis AU - Hosen Kiat Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/29/2021.05.26.21257833.abstract N2 - BACKGROUND Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons.OBJECTIVE To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT).METHODS Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%.RESULTS Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p<0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed.CONCLUSIONS PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted.TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p, registered on 12/01/2018Competing Interest StatementAL and BB, since February 2020, are co-founders, directors and current employees of SYMBYX Pty Ltd, a med-tech company developing treatments for neurological disorders. BB is an agent for Spectro Analytic Irradia AB, a laser manufacturer. The other authors declare that they have no competing interests.Clinical TrialAustralian New Zealand Clinical Trials Registry: ACTRN12618000038291pFunding StatementThe study was funded by grants from Parkinson's South Australia, the San Foundation, the Cardiac Health Institute and donations from anonymous donors. Laser devices used in the study were supplied by SUMOLITE Pty Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received human research ethics approval by the Griffith University Human Research Ethics Committee (2018/16). All participants gave written informed consent prior to taking part in the study. All protocols were approved by the Griffith University Human Research Ethics Committee and were conducted in accordance with their regulations and guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated and analysed during this study for this report are included in this published article and its supplementary information files. Additional study data can be requested from the corresponding author on request.10MWT10 metre walk testANOVAanalysis of varianceANZCTRAustralian New Zealand Clinical Trials registryATPadenosine triphosphatecAMPcyclic adenosine monophosphateCONSORTConsolidated Standards of Reporting TrialsCOVIDcoronavirus disease of 2019LEDlight emitting diodeMCIDminimal clinically important differenceMDS UPDRSMovement Disorder Society Unified Parkinson’s Disease Rating ScaleMoCAMontreal cognitive assessmentMPTP - 1methyl-4-phenyl-1,2,3,6-tetrahydropyridineNHPTnine-hole peg testNOnitric oxidePDParkinson’s diseasePBMphotobiomodulationRCTrandomized placebo-controlled trialROSreactive oxygen speciesSASouth AustraliaSLSsingle leg stanceTStandem stanceTUGtimed up and goWHOWorld Health Organisation ER -